Previous Close | 3.8600 |
Open | 3.8900 |
Bid | 3.8800 x 100 |
Ask | 3.9100 x 100 |
Day's Range | 3.8600 - 3.9200 |
52 Week Range | 3.3000 - 7.0000 |
Volume | |
Avg. Volume | 976,404 |
Market Cap | 223.821M |
Beta (5Y Monthly) | 0.76 |
PE Ratio (TTM) | 97.25 |
EPS (TTM) | 0.0400 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.25 |
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.